AbbVie price target raised to $226 from $215 at Citi
The Fly

AbbVie price target raised to $226 from $215 at Citi

Citi analyst Geoff Meacham raised the firm’s price target on AbbVie (ABBV) to $226 from $215 and keeps a Buy rating on the shares. AbbVie reported another solid quarter, says Citi, which remains bullish on the shares, citing the company’s many pipeline events and good commercial momentum for 2025.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App